The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with a novel coronavirus identified in Wuhan, China.
To expedite the shipment of clinical samples from patients with suspected COVID-19 virus infection from the country of collection to one of the WHO reference laboratories providing confirmatory testing for COVID-19, a shipment mechanism has been established.
This document provides guidance to Member States on implementation of global surveillance of COVID-19. The objectives of this global surveillance are:
1.to monitor trends of the disease where human to human transmission occurs;
2.rapidly detect new cases in countries where the virus is not circulating;
3.provide epidemiological information to conduct risk assessments at the national, regional and global level; and
In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named “2019 novel coronavirus (2019-nCoV)” by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual.
This document provides guidance to Member States on implementation of global surveillance of 2019-nCoV. The objectives of this global surveillance are to monitor trends of the disease where human to human and/or zoonotic transmission occurs;rapidly detect new cases in countries where the virus is not circulating; provide epidemiological information to conduct risk assessment at the national, regional and global level; and provide epidemiological information to guide response measures.
The following protocol has been designed to investigate the First Few X cases (FFX) and their close contacts. It is envisioned that the FFX 2019-nCoV investigation will be conducted across several countries or sites with geographical and demographical diversity.
This document is intended for clinicians taking care of hospitalised adult and paediatric patients with severe acute respiratory infection (SARI) when a nCoV infection is suspected. It is not meant to replace clinical judgment or specialist consultation but rather to strengthen clinical management of these patients and provide to up-to-date guidance.
The household transmission investigation is a case-ascertained prospective study of all identified household contacts of a laboratory confirmed 2019-nCoV infection (see 2.2 Study population). It is intended to provide rapid and early information on the clinical, epidemiological and virological characteristics of 2019-nCoV.
WHO has developed this rapid advice note to meet the need for recommendations on the safe home care for patients with suspected novel coronavirus (2019-nCoV) infection presenting with mild symptoms and public health measures
This is the first edition of guidance on infection prevention and control (IPC) strategies for use when infection with a novel coronavirus (2019-nCoV) is suspected. It has been adapted from WHO’s Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection…
This document provides WHO checklists for risk communication and community engagement (RCCE) readiness and initial response for novel coronaviruses (nCoV) recently identified in Wuhan, China (2019-nCoV). The objective of this document is to provide actionable guidance for countries to implement effective RCCE strategies which will help protect the public’s health in the early response to nCoV.